All Studies Meta Analysis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Camostat Mesilate for Treatment of COVID-19 in Outpatients

Sagent Pharmaceuticals, NCT04583592, NCT04583592

Mar 2021

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Download Image

RCT 295 outpatients in the USA, showing no significant differences with camostat.

Important missing comments or errors? Let us know.

risk of death, 152.1% higher, RR 2.52, p = 1.00, treatment 1 of 194 (0.5%), control 0 of 101 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 28.

ER, hospitalization, death, 13.2% lower, RR 0.87, p = 0.79, treatment 10 of 194 (5.2%), control 6 of 101 (5.9%), NNT 127.

risk of no viral clearance, 16.1% lower, RR 0.84, p = 0.36, treatment 58 of 194 (29.9%), control 36 of 101 (35.6%), NNT 17, day 15.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Sagent Pharmaceuticals et al., 31 Mar 2021, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04583592 (history). Contact: ctinkoff@sagentpharma.com.

This Paper Camostat All

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0